Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 9328347, 10 pages
Review Article

Mesenchymal Stem Cells Improve Healing of Diabetic Foot Ulcer

Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun 130021, China

Correspondence should be addressed to Guixia Wang; nc.ude.ulj@861gnawg

Received 24 September 2016; Accepted 28 February 2017; Published 12 March 2017

Academic Editor: Ruozhi Zhao

Copyright © 2017 Yue Cao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Mesenchymal stem cells (MSCs), an ideal cell source for regenerative therapy with no ethical issues, play an important role in diabetic foot ulcer (DFU). Growing evidence has demonstrated that MSCs transplantation can accelerate wound closure, ameliorate clinical parameters, and avoid amputation. In this review, we clarify the mechanism of preclinical studies, as well as safety and efficacy of clinical trials in the treatment of DFU. Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.